Affordable Access

Publisher Website

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

Authors
Publisher
Elsevier Ltd
Publication Date
Volume
28
Issue
45
Identifiers
DOI: 10.1016/j.vaccine.2010.08.075
Keywords
  • Influenza Vaccine
  • Mf59 Adjuvant
  • Children
  • Adolescents
Disciplines
  • Medicine

Abstract

Abstract We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents (aged 6 months–18 years) in an integrated analysis of all pediatric trials evaluating MF59-containing influenza vaccines completed to date (5 trials). In the MF59-adjuvanted group ( n = 1181) versus the non-adjuvanted group ( n = 545) there was no increase in the incidence of unsolicited adverse events and serious adverse events. As expected, solicited local or systemic reactions occurred more frequently in MF59-adjuvanted subjects; however, a majority of reactions were mild and transient. These data support the safety of MF59-adjuvanted influenza vaccines in the pediatric population.

There are no comments yet on this publication. Be the first to share your thoughts.